Mission Possible: Advances in MYC Therapeutic Targeting in Cancer

被引:116
作者
Allen-Petersen, Brittany L. [1 ]
Sears, Rosalie C. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, RLSB, 2730 SW Moody Ave, Portland, OR 97201 USA
基金
美国国家卫生研究院;
关键词
PROLYL-ISOMERASE PIN1; PROTEIN PHOSPHATASE 2A; TUMOR-SUPPRESSOR PP2A; CHRONIC LYMPHOCYTIC-LEUKEMIA; HER2-POSITIVE BREAST-CANCER; INHIBITOR BI 894999; CELL-CYCLE ARREST; GROWTH IN-VITRO; C-MYC; BET BROMODOMAIN;
D O I
10.1007/s40259-019-00370-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MYC is a master transcriptional regulator that controls almost all cellular processes. Over the last several decades, researchers have strived to define the context-dependent transcriptional gene programs that are controlled by MYC, as well as the mechanisms that regulate MYC function, in an effort to better understand the contribution of this oncoprotein to cancer progression. There are a wealth of data indicating that deregulation of MYC activity occurs in a large number of cancers and significantly contributes to disease progression, metastatic potential, and therapeutic resistance. Although the therapeutic targeting of MYC in cancer is highly desirable, there remain substantial structural and functional challenges that have impeded direct MYC-targeted drug development and efficacy. While efforts to drug the 'undruggable' may seem futile given these challenges and considering the broad reach of MYC, significant strides have been made to identify points of regulation that can be exploited for therapeutic purposes. These include targeting the deregulation of MYC transcription in cancer through small-molecule inhibitors that induce epigenetic silencing or that regulate the G-quadruplex structures within the MYC promoter. Alternatively, compounds that disrupt the DNA-binding activities of MYC have been the long-standing focus of many research groups, since this method would prevent downstream MYC oncogenic activities regardless of upstream alterations. Finally, proteins involved in the post-translational regulation of MYC have been identified as important surrogate targets to reduce MYC activity downstream of aberrant cell stimulatory signals. Given the complex regulation of the MYC signaling pathway, a combination of these approaches may provide the most durable response, but this has yet to be shown. Here, we provide a comprehensive overview of the different therapeutic strategies being employed to target oncogenic MYC function, with a focus on post-translational mechanisms.
引用
收藏
页码:539 / 553
页数:15
相关论文
共 252 条
[1]   The ubiquitin ligase HectH9 regulates transcriptional activation by myc and is essential for tumor cell proliferation [J].
Adhikary, S ;
Marinoni, F ;
Hock, A ;
Hulleman, E ;
Popov, N ;
Beier, R ;
Bernard, S ;
Quarto, M ;
Capra, M ;
Goettig, S ;
Kogel, U ;
Scheffner, M ;
Helin, K ;
Eilers, M .
CELL, 2005, 123 (03) :409-421
[2]   Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia [J].
Agarwal, Anupriya ;
MacKenzie, Ryan J. ;
Pippa, Raffaella ;
Eide, Christopher A. ;
Oddo, Jessica ;
Tyner, Jeffrey W. ;
Sears, Rosalie ;
Vitek, Michael P. ;
Odero, Maria D. ;
Christensen, Dale J. ;
Druker, Brian J. .
CLINICAL CANCER RESEARCH, 2014, 20 (08) :2092-2103
[3]   c-Myc Inhibitor 10074-G5 Induces Murine and Human Hematopoietic Stem and Progenitor Cell Expansion and HDR Modulator Rad51 Expression [J].
Aksoz, Merve ;
Albayrak, Esra ;
Aslan, Galip Servet ;
Turan, Raife Dilek ;
Alyazici, Lamia Yazgi ;
Siyah, Pinar ;
Tuysuz, Emre Can ;
Canikyan, Serli ;
Yucel, Dogacan ;
Meric, Neslihan ;
Gulbas, Zafer ;
Sahin, Fikrettin ;
Kocabas, Fatih .
CURRENT CANCER DRUG TARGETS, 2019, 19 (06) :479-494
[4]   Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma [J].
Allen-Petersen, Brittany L. ;
Risom, Tyler ;
Feng, Zipei ;
Wang, Zhiping ;
Thoma, Mary C. ;
Pelz, Katherine R. ;
Morton, Jennifer P. ;
Sansom, Owen J. ;
Lopez, Charles D. ;
Sheppard, Brett ;
Christensen, Dale J. ;
Ohlmeyer, Michael ;
Narla, Goutham ;
Sears, Rosalie C. .
CANCER RESEARCH, 2019, 79 (01) :209-219
[5]   Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis [J].
Andrews, Forest H. ;
Singh, Alok R. ;
Joshi, Shweta ;
Smith, Cassandra A. ;
Morales, Guillermo A. ;
Garlich, Joseph R. ;
Durden, Donald L. ;
Kutateladze, Tatiana G. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (07) :E1072-E1080
[6]   Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis [J].
Annibali, Daniela ;
Whitfield, Jonathan R. ;
Favuzzi, Emilia ;
Jauset, Toni ;
Serrano, Erika ;
Cuartas, Isabel ;
Redondo-Campos, Sara ;
Folch, Gerard ;
Gonzalez-Junca, Alba ;
Sodir, Nicole M. ;
Masso-Valles, Daniel ;
Beaulieu, Marie-Eve ;
Swigart, Lamorna B. ;
Mc Gee, Margaret M. ;
Somma, Maria Patrizia ;
Nasi, Sergio ;
Seoane, Joan ;
Evan, Gerard I. ;
Soucek, Laura .
NATURE COMMUNICATIONS, 2014, 5
[7]   Protein phosphatase 2A regulatory subunit b56α associates with c-Myc and negatively regulates c-Myc accumulation [J].
Arnold, HK ;
Sears, RC .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (07) :2832-2844
[8]   A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins [J].
Arnold, Hugh K. ;
Sears, Rosalie C. .
CANCER AND METASTASIS REVIEWS, 2008, 27 (02) :147-158
[9]   The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc [J].
Arnold, Hugh K. ;
Zhang, Xiaoli ;
Daniel, Colin J. ;
Tibbitts, Deanne ;
Escamilla-Powers, Julie ;
Farrell, Amy ;
Tokarz, Sara ;
Morgan, Charlie ;
Sears, Rosalie C. .
EMBO JOURNAL, 2009, 28 (05) :500-512
[10]  
Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]